These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 24850081)

  • 1. Clinical and pathological features of Parkinson's disease.
    Schneider SA; Obeso JA
    Curr Top Behav Neurosci; 2015; 22():205-20. PubMed ID: 24850081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathological changes in dendrites of substantia nigra neurons in Parkinson's disease: a Golgi study.
    Patt S; Gertz HJ; Gerhard L; Cervós-Navarro J
    Histol Histopathol; 1991 Jul; 6(3):373-80. PubMed ID: 1725760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. α-Synuclein in the olfactory system in Parkinson's disease: role of neural connections on spreading pathology.
    Ubeda-Bañon I; Saiz-Sanchez D; de la Rosa-Prieto C; Martinez-Marcos A
    Brain Struct Funct; 2014 Sep; 219(5):1513-26. PubMed ID: 24135772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pathophysiology of sporadic Parkinson's disease].
    Braak H; Del Tredici K
    Fortschr Neurol Psychiatr; 2010 Mar; 78 Suppl 1():S2-4. PubMed ID: 20195936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurofilament mRNA is reduced in Parkinson's disease substantia nigra pars compacta neurons.
    Hill WD; Arai M; Cohen JA; Trojanowski JQ
    J Comp Neurol; 1993 Mar; 329(3):328-36. PubMed ID: 8459049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alpha-synuclein pathology in Parkinson's and Alzheimer's disease brain: incidence and topographic distribution--a pilot study.
    Jellinger KA
    Acta Neuropathol; 2003 Sep; 106(3):191-201. PubMed ID: 12845452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
    Novikova L; Garris BL; Garris DR; Lau YS
    Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Etiology and pathogenesis of Parkinson's disease.
    Olanow CW; Tatton WG
    Annu Rev Neurosci; 1999; 22():123-44. PubMed ID: 10202534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T2-weighted MRI in Parkinson's disease; substantia nigra pars compacta hypointensity correlates with the clinical scores.
    Atasoy HT; Nuyan O; Tunc T; Yorubulut M; Unal AE; Inan LE
    Neurol India; 2004 Sep; 52(3):332-7. PubMed ID: 15472421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The second brain and Parkinson's disease.
    Lebouvier T; Chaumette T; Paillusson S; Duyckaerts C; Bruley des Varannes S; Neunlist M; Derkinderen P
    Eur J Neurosci; 2009 Sep; 30(5):735-41. PubMed ID: 19712093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can Parkinson's disease pathology be propagated from one neuron to another?
    Dunning CJ; Reyes JF; Steiner JA; Brundin P
    Prog Neurobiol; 2012 May; 97(2):205-19. PubMed ID: 22115849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stanley Fahn Lecture 2005: The staging procedure for the inclusion body pathology associated with sporadic Parkinson's disease reconsidered.
    Braak H; Bohl JR; Müller CM; Rüb U; de Vos RA; Del Tredici K
    Mov Disord; 2006 Dec; 21(12):2042-51. PubMed ID: 17078043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Controversy: is Parkinson's disease a single disease entity? Yes.
    Takahashi H; Wakabayashi K
    Parkinsonism Relat Disord; 2005 Jun; 11 Suppl 1():S31-7. PubMed ID: 15885626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Selective stimulations and lesions of the rat brain nuclei as the models for research of the human sleep pathology mechanisms].
    Šaponjić J
    Glas Srp Akad Nauka Med; 2011; (51):85-97. PubMed ID: 22165729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroinflammation in Alzheimer's disease and Parkinson's disease: are microglia pathogenic in either disorder?
    Rogers J; Mastroeni D; Leonard B; Joyce J; Grover A
    Int Rev Neurobiol; 2007; 82():235-46. PubMed ID: 17678964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
    Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
    Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The progression of pathology in longitudinally followed patients with Parkinson's disease.
    Halliday G; Hely M; Reid W; Morris J
    Acta Neuropathol; 2008 Apr; 115(4):409-15. PubMed ID: 18231798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. When does Parkinson's disease begin?
    Gaig C; Tolosa E
    Mov Disord; 2009; 24 Suppl 2():S656-64. PubMed ID: 19877243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Parkinson's disease: a short story of 200 years.
    Cuenca L; Gil-Martinez AL; Cano-Fernandez L; Sanchez-Rodrigo C; Estrada C; Fernandez-Villalba E; Herrero MT
    Histol Histopathol; 2019 Jun; 34(6):573-591. PubMed ID: 30540129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lewy-body formation is an aggresome-related process: a hypothesis.
    Olanow CW; Perl DP; DeMartino GN; McNaught KS
    Lancet Neurol; 2004 Aug; 3(8):496-503. PubMed ID: 15261611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.